IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase II trial revealed that felzartamab, an ...

Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult ...

CAMBRIDGE, Mass., Oct. 26, 2024-- Biogen Inc.– today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in people ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an ...

Felzartamab, an investigational antibody, reduces triggers linked to IgA nephropathy, an autoimmune kidney disease, suggesting lasting clinical benefits. About Careers Internship MedBlog Contact us ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Biogen acquired the rights to felzartamab, which is already in Phase 3 studies in late antibody-mediated rejection in adult kidney transplant recipients and in IgA nephropathy, as part of last ...

Through analyses of patient blood samples, scientists have revealed previously unknown mechanisms behind felzartamab’s efficacy and tolerability in IgA nephropathy. Results from the study will ...

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an ...

--Biogen Inc.– today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in people living with IgA nephropathy. The ...

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an ...

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024. Oct. 26, 2024 8:15 PM ET Biogen Inc. (BIIB) ...